Peginterferon Alfa-2b and Ribavirin Combination Therapy for Chronic Hepatitis C

• Armstrong GL , WasleyA, SimardEP, McQuillanGM, KuhnertWL, AlterMJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.Ann. Intern. Med.144(10), 705–714 (2006).
   PubMed Web of Science ®Google Scholar
• Perz J et al. : Estimated global prevalence of hepatitis C infection. Presented at: 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA 30 September 2004.
   Google Scholar
• Centers for Disease Control: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb Mortal Wkly Rep.47(RR-19), 1–39 (1998).
   PubMedGoogle Scholar
• Alter MJ , Kruszon-MoranD, NainanOVet al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.N. Engl. J. Med.341(8), 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Pessoa MG , WrightTL: Hepatitis C infection in transplantation.Clin. Liver Dis.1, 663–690 (1997).
   PubMedGoogle Scholar
• Armstrong GL , AlterMJ, McQuillanGM, Margolis HS: The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology31, 777–782 (2003)
   Google Scholar
• Bialek SR , TerraultNA: The changing epidemiology and natural history of hepatitis C virus infection.Clin. Liver Dis.10(4), 697–715 (2006).
   PubMedGoogle Scholar
• Bukh J , MillerRH, PurcellRH: Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.Sem. Liver Dis.15(1), 41–63 (1995).
   PubMed Web of Science ®Google Scholar
• Simmonds P , MellorJ, CraxiAet al.: Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients.J. Hepatol.24(5), 517–524 (1996).
   PubMed Web of Science ®Google Scholar
• Formann E , Steindl-MundaP, HoferHet al.: Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.Aliment. Pharmacol. Ther.23(4), 507–511 (2006).
   PubMed Web of Science ®Google Scholar
• Lau DT , KleinerDE, GhanyMG, ParkY, SchmidP, HoffnagleJH: 10-Year follow-up after interferon-alfa therapy for chronic hepatitis C.Hepatology28, 1121–1127 (1998).
   PubMed Web of Science ®Google Scholar
• Swain MG , LaiMY, ShiffmanML et al: Durable sustained virological response after treatment with peginterferon alfa-2a alone or in combination with ribavirin: 5-year follow-up and the criteria of a cure. Presented at: 42nd Annual Meeting of the European Association for the Study of Liver Diseases. Barcelona, Spain, 11–15 April 2007.
   Google Scholar
• Myers RP , RegimbeauC, ThevenotTet al.: Interferon for interferon naive patients with chronic hepatitis C.Cochrane Database Syst. Rev. Art. No.: CD000370. DOI: 10.1002/14651858.CD000370 (2002).
   Google Scholar
• Poynard T , LeroyV, CohardMet al.: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.Hepatology24, 778–789 (1996).
   PubMed Web of Science ®Google Scholar
• McHutchison JG , GordonSC, SchiffERet al.: Interferon-alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med.339, 1485–1492 (1998).
   PubMed Web of Science ®Google Scholar
• Glue P , FangJW, Rouzier-PanisRet al. (For the Hepatitis C Intervention Therapy Group): Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68, 556–567 (2000).
   PubMed Web of Science ®Google Scholar
• Manns MP , McHutchisonJG, GordonSCet al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW , ShiffmanMI, ReddyRet al.: Peginterferon-alfa 2a plus ribavirin for chronic Hepatitis C infection.N. Engl. J. Med.347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• PEG-Intron™, package insert. Schering Corporation, Kenilworth, NJ, USA (2001).
   Google Scholar
• Pegasys™, package insert. Hoffman-La Roche Inc, Nutley, NJ, USA (2002, revised 2004).
   Google Scholar
• Dixit NM , Layden-AlmerJE, LaydenTJ, PerelsonAS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.Nature432(7019), 922–924 (2004).
   PubMed Web of Science ®Google Scholar
• Lau JYN , TamRC, LiangTJ, HongZ: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.Hepatology35(5), 1002–1009 (2002).
   PubMed Web of Science ®Google Scholar
• Luxon B , GraceM, BrassardD, BordensR: Pegylated interferons for the treatment of chronic hepatitis C infection.Clin. Ther.24(9), 1363–1383 (2002).
   PubMed Web of Science ®Google Scholar
• Wang YS , YoungsterS, BauschJ, ZhangR, McNemarC, WyssDF: Identification of the major positional isomer of pegylated interferon alpha-2b.Biochemistry39, 10634–10640 (2000).
   PubMed Web of Science ®Google Scholar
• Copegus™, package insert. Roche Pharmaceuticals, Nutley, NJ, USA (2002).
   Google Scholar
• Rebetol™, package insert. Schering Corporation, Kenilworth, NJ, USA (1998, revised 2006).
   Google Scholar
• Carrat F , Bani-SadrF, PolSet al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.JAMA292(23), 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Muir AJ , BornsteinJD, KillenbergPG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.N. Engl. J. Med.350, 2265–2271 (2004).
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS , KleinerDE, EverhartJEet al.: Race, insulin resistance and hepatic steatosis in chronic hepatitis C.Hepatology45, 80–87 (2007).
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 10–12 June, 2002. Hepatology36(Suppl. 1), S3–S20 (2002).
   PubMed Web of Science ®Google Scholar
• Dienstag JL , McHutchisonJG: American Gastroenterological Association technical review on the management of hepatitis C.Gastroenterology130(1), 231–264 (2006).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ , SetteHJr, MorganTRet al.: Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of duration and ribavirin dose. Ann. Intern. Me.140, 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Zeuzem S , HultcrantzR, BourliereMet al.: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.J. Hepatol.40(6), 993–999 (2004).
   PubMed Web of Science ®Google Scholar
• Mangia A , SantoroR, MinervaNet al.: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.N. Engl. J. Med.352(25), 2609–2617 (2005).
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M , ComanorL, Minor JMet al.: Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. J. Viral Hepat.13(10), 701–707 (2006).
   PubMed Web of Science ®Google Scholar
• Davis GL , WongJB, McHutchisonJG, MannsMP, HarveyJ, AlbrechtJ: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Hepatology38(3), 645–652 (2003).
   PubMed Web of Science ®Google Scholar
• Davis GL : Monitoring of viral levels during therapy of hepatitis C.Hepatology36, S141–151 (2002).
   Google Scholar
• McHutchison JG , MannsM, PatelKet al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Gastroenterology123(4), 1061–1069 (2002).
   PubMed Web of Science ®Google Scholar
• Duronte-Mangoni E , IardinoP, UtiliR, AdinolfiLE, RuggieroG: Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.Antivir. Ther.11(5), 637–640 (2006).
   PubMed Web of Science ®Google Scholar
• McHutchison JG , AfdhalNH, DusheikoGet al.: Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a Phase II placebo controlled, double - blind, dose - ranging study.Proceedings of the 57th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA 27–31 October 2006.
   Google Scholar
• Kee KM , LeeCM, WangJHet al.: Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.J. Gastroenterol. Hepatol.21(1 Pt 2), 319–326 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno Planas JM , Rubio GonzalezE, Boullosa GranaEet al.: Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis. Transplant. Proc.37(3), 1482–1483 (2005).
   PubMed Web of Science ®Google Scholar
• Iacobellis A , SicilianoM, PerriFet al.: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.J. Hepatol.46(2), 206–212 (2007).
   PubMed Web of Science ®Google Scholar
• Horoldt B , HaydonG, O‘DonnellK, DudleyT, NightingaleP, MutimerD: Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.Liver Int.26(6), 650–659 (2006).
   PubMed Web of Science ®Google Scholar
• Data on file. Final Report: Comparison of peg interferon alfa-2b (PEG-Intron®, SCH 54031) plus Rebetol® (SCH 18908) vs interferon alfa-2b (Intron A®, SCH 30500) plus Rebetol® for treatment of chronic hepatitis C in previously untreated adult subjects. Protocol No. C/198–580. Schering-Plough Corporation, NJ, USA.
   Google Scholar

Websites

• Federal Drug Administration. Information for Healthcare Professionals Erythropoiesis Stimulating Agents (ESA), 2006 (updated 2007) www.fda.gov/cder/drug/InfoSheets/HCP/ RHE2007HCP.htm
   Google Scholar
• European Medicines Agency. European Public Assessment Report for authorised medicinal products for human use — PegIntron www.emea.europa.eu/humandocs/Humans/EPAR/pegintron/pegintron.htm
   Google Scholar
• Federal Drug Administration. Peg-Intron Product Approval Information - Licensing Action, January 19, 2001 www.fda.gov/cder/foi/appletter/2001/pegsche011901L.htm
   Google Scholar
• Federal Drug Administration. Peg-Intron and Ribavirin Product Approval Information - Licensing Action, August 7, 2001 www.fda.gov/cder/foi/appletter/2001/pegsche080701L.htm
   Google Scholar
• European Medicines Agency. European Public Assessment Report for authorised medicinal products for human use — Rebetol www.emea.europa.eu/humandocs/Humans/EPAR/rebetol/rebetol.htm
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use —Post-Authorisation Summary of Positive Opinion for PegIntron www.emea.europa.eu/pdfs/human/opinion/18609307en.pdf
   Google Scholar